title: Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
abstract: Twenty-four patients were given the combination of methylprednisolone 100 mg i.v. on day 0, cyclosporine 2 mg/kg i.v. every 12 h starting on day -3 and methotrexate 5 mg/m2 on days 1, 3, and 6, then 10 mg/m2 on days 11 and 18 after allogeneic bone marrow transplantation for hematological malignancies for the prophylaxis of acute graft-versus-host disease. (GVHD). Methylprednisolone was given prior to the marrow infusion for its lympholytic effect. The methotrexate dose on days 1, 3, and 6 was half of that given in other studies to decrease the early toxicities. The outcome of this group is compared with patients transplanted before 1988 and given methotrexate alone, methotrexate with prednisone, or cyclosporine alone. There is no difference in relapse and survival between the groups at this time. The rate of engraftment and incidence of mucositis with the combination is not significantly different from the cyclosporine group. No patient developed greater than grade II acute GVHD with the combination. The probability of grade II or higher acute GVHD with the combination (14%) is significantly less than methotrexate, with or without prednisone or cyclosporine alone.
authors.affiliation: Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: J C
authors.initials: JC
authors.lastname: Yau
authors.forename: C F
authors.initials: CF
authors.lastname: LeMaistre
authors.forename: G K
authors.initials: GK
authors.lastname: Zagars
authors.forename: L A
authors.initials: LA
authors.lastname: Williams
authors.forename: C M
authors.initials: CM
authors.lastname: Meneghetti
authors.forename: D R
authors.initials: DR
authors.lastname: Luke
authors.forename: F R
authors.initials: FR
authors.lastname: Dunphy
authors.forename: J A
authors.initials: JA
authors.lastname: Spinolo
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: G
authors.initials: G
authors.lastname: Spitzer
mesh_terms: D000293:Adolescent; D000328:Adult; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004359:Drug Therapy, Combination; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged
chemical_list: D003524:Cyclosporins; D008775:Methylprednisolone; D008727:Methotrexate